New drug combined therapy for untreated multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares a new drug (HLX15-IV) with a standard treatment (Darzalex) when both are combined with lenalidomide and dexamethasone, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been recently diagnosed with multiple myeloma and have not yet had any treatment for it.
- You are not a candidate for a stem cell transplant (doctors have decided that transplant is not a good option for you).
- You are fully active (able to do all your normal daily activities without help).
- You do not have asthma or COPD (chronic lung disease) now, and you haven't had asthma in the past 2 years.
- You do not have a history of any other cancer in the last 3 years (except multiple myeloma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
This trial tests a new drug called linperlisib (which targets a specific protein in cancer cells) combined with a standard three-drug regimen (VRD) for people newly diagnosed with multiple myeloma. It aims to see if this combination is safe and works well before a stem cell transplant.
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.